dhuVHH6-PE38

dhuVHH6-PE38 is a humanized, bivalent nanobody-based recombinant immunotoxin developed for the treatment of CD7-positive malignancies, particularly T-cell acute lymphoblastic leukemia (T-ALL). It consists of a humanized camelid-derived single-domain antibody (nanobody) targeting the CD7 antigen, fused to PE38, a 38 kDa truncated form of Pseudomonas exotoxin A. The drug works by binding specifically to CD7 on the surface of malignant T-cells, triggering rapid internalization via endocytosis. Once inside the cell, the PE38 toxin moiety is released into the cytoplasm, where it catalyzes the ADP-ribosylation of elongation factor 2 (EF-2), thereby halting protein synthesis and inducing apoptosis. Pre-clinical studies have demonstrated that dhuVHH6-PE38 possesses high specificity, potent in vitro cytotoxicity against T-ALL cell lines and primary patient samples, and significant antitumor activity in patient-derived xenograft (PDX) mouse models with a favorable safety profile.

Other names

humanized CD7 nanobody immunotoxin